Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 28, 2024 16:30 ET
|
Pyxis Oncology
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
March 27, 2024 07:30 ET
|
Pyxis Oncology
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s...
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
March 21, 2024 07:30 ET
|
Pyxis Oncology
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private...
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
March 13, 2024 08:00 ET
|
Pyxis Oncology
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
March 07, 2024 16:30 ET
|
Pyxis Oncology
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
March 05, 2024 16:45 ET
|
Pyxis Oncology
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models The PYX-201 target EDB+FN is found overexpressed...
Pyxis Oncology Announces $50 Million Private Placement
February 27, 2024 08:00 ET
|
Pyxis Oncology
BOSTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29, 2023 16:30 ET
|
Pyxis Oncology
BOSTON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
November 28, 2023 07:00 ET
|
Pyxis Oncology
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today...
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
November 07, 2023 16:30 ET
|
Pyxis Oncology
PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data...